Syndax Pharmaceuticals Inc. has announced new compensation terms under its 2023 Inducement Plan, granting inducement awards to seven new employees. The awards include options to purchase up to 48,600 shares of common stock. The stock options will vest over a period of four years, with 25% of the shares vesting on the first anniversary of the vesting commencement date. Subsequently, 1/48th of the shares will vest monthly over the next 36 months, contingent upon the continuation of the employees' service with the company. This plan aims to align employee interests with the company's long-term success.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。